ASCO Guideline Update: Use of immune checkpoint inhibitor Pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer.

Use of Immune Checkpoint Inhibitor Pembrolizumab in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update – Journal of Clinical Oncology